Guggenheim kept Buy rating on Johnson & Johnson stock

Published on 10/12/2026 at 11:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Johnson & Johnson stock costs EUR 233.85 on October 12, 2026, 0.99 percent above the Xetra close. Third-quarter results are due October 13, 2026.

Key points in brief

Guggenheim reiterated a Buy rating and a USD 287.00 target on October 7, 2026.
Johnson & Johnson stock was EUR 233.85 at Lang & Schwarz on October 12, 2026, 0.99 percent above the Xetra close of October 9, 2026 at EUR 231.55.
Second-quarter 2026 reported sales reached USD 25.31 billion, up 6.60 percent year over year, while adjusted earnings per share rose to USD 2.90.
Third-quarter results are scheduled for October 13, 2026, with a December 8, 2026 business review also ahead.

Architectural interior of a modern pharmaceutical research campus with a soaring glass-walled atrium, a long rectangular reflecting pool through its center, white-coated researchers walking past lush indoor plants, clean white concrete columns bathed in d — Johnson investiert in Pharma Forschung, US4781601046 Atrium mit Wasserbecken und hellem Tageslicht, Illustration mit AI erstellt.

Johnson & Johnson (ISIN US4781601046) was priced at EUR 233.85 at Lang & Schwarz on October 12, 2026 at 11:01 a.m. CEST, 0.99 percent above the Xetra close of October 9, 2026 at EUR 231.55. On October 7, 2026, Guggenheim reiterated a Buy rating and a USD 287.00 price target, as Investing.com reported. The assessment arrives before the company reports its third-quarter results.

Three dates shape the setup

On July 15, 2026, Johnson & Johnson reported second-quarter sales of USD 25.31 billion, up 6.60 percent year over year, while adjusted earnings per share reached USD 2.90 versus USD 2.84 consensus, according to Yahoo Finance. The same report said adjusted earnings per share increased 4.70 percent from the prior-year period.

On October 2, 2026, Johnson & Johnson published two-year ICOTYDE psoriasis data: 60.00 percent of patients with scalp psoriasis and 89.00 percent with genital psoriasis achieved site-specific complete skin clearance at Week 112, according to Trivano.

On October 7, 2026, Guggenheim expected third-quarter revenue of USD 25.49 billion against USD 25.37 billion consensus and adjusted earnings per share of USD 2.49 against USD 2.69 consensus, according to Investing.com. That forecast places revenue above consensus but adjusted earnings per share below it, making the earnings release the immediate test for the valuation.

What dates matter next?

Johnson & Johnson is scheduled to report third-quarter 2026 results before the US market opens on October 13, 2026, according to Yahoo Finance. A December 8, 2026 Enterprise Business Review is also expected to address the potential of recent Innovative Medicine launches, according to Investing.com.

Price stays below the yearly high

Johnson & Johnson stock was at EUR 233.85 at Lang & Schwarz on October 12, 2026 at 11:01 a.m. CEST, 0.99 percent above the Xetra close of October 9, 2026 at EUR 231.55. The NYSE quote was USD 261.44 on October 9, 2026 at 4:00 p.m. ET, while the 52-week range was USD 184.66 to USD 281.07.

The further course of trading is shown by the continuously updated real-time quote of Johnson & Johnson stock.